BG-12 in multiple sclerosis
- PMID: 23709213
- DOI: 10.1055/s-0033-1343796
BG-12 in multiple sclerosis
Abstract
Dimethyl fumarate (DMF) is an orally administered agent that has been used for over 40 years for the treatment of psoriasis. Recent work demonstrates both DMF immunomodulatory and neuroprotective actions in vitro and in animal models of autoreactive central nervous system inflammation and neurodegeneration. DMF acts through chemical modification of the repressor protein Keap1, allowing stabilization and nuclear translocation of the transcription factor Nrf2, with subsequent downstream activation of a cascade of several cytoprotective and antioxidant pathways. Additionally, suppression of transcription factor NF-κB-mediated proinflammatory signaling results in the inhibition of proinflammatory responses and induction of anti-inflammatory cytokines. BG-12 is an orally administered, enteric-coated microtablet preparation of DMF. In two phase III, relapsing-remitting multiple sclerosis (MS) trials, BG-12 led to a 44 to 53% reduction in annualized relapse rate and a 71 to 85% reduction in new T2 lesions on magnetic resonance imaging. The most common side effects of BG-12 are cutaneous flushing and gastrointestinal symptoms, with the highest incidence in the first month after starting treatment. No serious safety signals were seen during the phase II and III trials, including no increased risk of opportunistic infections or cancer. Altogether, BG-12's novel mechanism of action appears to provide a favorable balance of efficacy, safety, and tolerability for treatment of relapsing MS.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Similar articles
-
Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.Expert Rev Clin Pharmacol. 2013 Jul;6(4):355-62. doi: 10.1586/17512433.2013.811826. Expert Rev Clin Pharmacol. 2013. PMID: 23927662 Review.
-
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Clinical Trial.
-
[Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].Ideggyogy Sz. 2015 Jan 30;68(1-2):7-14. Ideggyogy Sz. 2015. PMID: 25842911 Review. Hungarian.
-
Dimethyl fumarate for multiple sclerosis.Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12. doi: 10.1517/13543784.2010.534778. Epub 2010 Nov 11. Expert Opin Investig Drugs. 2010. PMID: 21067468 Review.
-
Dimethyl fumarate : a Janus-faced substance?Expert Opin Pharmacother. 2013 Aug;14(11):1559-67. doi: 10.1517/14656566.2013.804912. Epub 2013 May 22. Expert Opin Pharmacother. 2013. PMID: 23697607 Review.
Cited by
-
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal in Vivo Efficacy.ACS Med Chem Lett. 2023 Nov 21;14(12):1700-1706. doi: 10.1021/acsmedchemlett.3c00336. eCollection 2023 Dec 14. ACS Med Chem Lett. 2023. PMID: 38116420
-
Metabolomics Profile of the Secretome of Space-Flown Oligodendrocytes.Cells. 2023 Sep 11;12(18):2249. doi: 10.3390/cells12182249. Cells. 2023. PMID: 37759473 Free PMC article.
-
Novel potential pharmacological applications of dimethyl fumarate-an overview and update.Front Pharmacol. 2023 Sep 7;14:1264842. doi: 10.3389/fphar.2023.1264842. eCollection 2023. Front Pharmacol. 2023. PMID: 37745068 Free PMC article. Review.
-
Mechanism and Disease Association With a Ubiquitin Conjugating E2 Enzyme: UBE2L3.Front Immunol. 2022 Feb 21;13:793610. doi: 10.3389/fimmu.2022.793610. eCollection 2022. Front Immunol. 2022. PMID: 35265070 Free PMC article. Review.
-
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.Vaccines (Basel). 2020 Dec 26;9(1):12. doi: 10.3390/vaccines9010012. Vaccines (Basel). 2020. PMID: 33375365 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical